325 related articles for article (PubMed ID: 16221960)
1. Mode of action in relevance of rodent liver tumors to human cancer risk.
Holsapple MP; Pitot HC; Cohen SM; Boobis AR; Klaunig JE; Pastoor T; Dellarco VL; Dragan YP
Toxicol Sci; 2006 Jan; 89(1):51-6. PubMed ID: 16221960
[TBL] [Abstract][Full Text] [Related]
2. Cancer risk assessment for 1,3-butadiene: data integration opportunities.
Preston RJ
Chem Biol Interact; 2007 Mar; 166(1-3):150-5. PubMed ID: 16647696
[TBL] [Abstract][Full Text] [Related]
3. Mode-of-action analysis for induction of rat liver tumors by pyrethrins: relevance to human cancer risk.
Osimitz TG; Lake BG
Crit Rev Toxicol; 2009; 39(6):501-11. PubMed ID: 19463055
[TBL] [Abstract][Full Text] [Related]
4. Rodent carcinogenicity of peroxisome proliferators and issues on human relevance.
Lai DY
J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2004 May; 22(1):37-55. PubMed ID: 15845221
[TBL] [Abstract][Full Text] [Related]
5. Formaldehyde and glutaraldehyde and nasal cytotoxicity: case study within the context of the 2006 IPCS Human Framework for the Analysis of a cancer mode of action for humans.
McGregor D; Bolt H; Cogliano V; Richter-Reichhelm HB
Crit Rev Toxicol; 2006; 36(10):821-35. PubMed ID: 17118731
[TBL] [Abstract][Full Text] [Related]
6. Chloroform mode of action: implications for cancer risk assessment.
Golden RJ; Holm SE; Robinson DE; Julkunen PH; Reese EA
Regul Toxicol Pharmacol; 1997 Oct; 26(2):142-55. PubMed ID: 9356278
[TBL] [Abstract][Full Text] [Related]
7. Mode-of-action framework for evaluating the relevance of rodent forestomach tumors in cancer risk assessment.
Proctor DM; Gatto NM; Hong SJ; Allamneni KP
Toxicol Sci; 2007 Aug; 98(2):313-26. PubMed ID: 17426108
[TBL] [Abstract][Full Text] [Related]
8. Development of a quantitative model incorporating key events in a hepatotoxic mode of action to predict tumor incidence.
Luke NS; Sams R; DeVito MJ; Conolly RB; El-Masri HA
Toxicol Sci; 2010 May; 115(1):253-66. PubMed ID: 20106946
[TBL] [Abstract][Full Text] [Related]
9. IPCS framework for analyzing the relevance of a cancer mode of action for humans.
Boobis AR; Cohen SM; Dellarco V; McGregor D; Meek ME; Vickers C; Willcocks D; Farland W
Crit Rev Toxicol; 2006; 36(10):781-92. PubMed ID: 17118728
[TBL] [Abstract][Full Text] [Related]
10. Human relevance framework for rodent liver tumors induced by the insecticide sulfoxaflor.
LeBaron MJ; Gollapudi BB; Terry C; Billington R; Rasoulpour RJ
Crit Rev Toxicol; 2014 May; 44 Suppl 2():15-24. PubMed ID: 24832551
[TBL] [Abstract][Full Text] [Related]
11. A cancer risk assessment of di(2-ethylhexyl)phthalate: application of the new U.S. EPA Risk Assessment Guidelines.
Doull J; Cattley R; Elcombe C; Lake BG; Swenberg J; Wilkinson C; Williams G; van Gemert M
Regul Toxicol Pharmacol; 1999 Jun; 29(3):327-57. PubMed ID: 10388618
[TBL] [Abstract][Full Text] [Related]
12. An evaluation of the mode of action framework for mutagenic carcinogens case study: Cyclophosphamide.
McCarroll N; Keshava N; Cimino M; Chu M; Dearfield K; Keshava C; Kligerman A; Owen R; Protzel A; Putzrath R; Schoeny R
Environ Mol Mutagen; 2008 Mar; 49(2):117-31. PubMed ID: 18240158
[TBL] [Abstract][Full Text] [Related]
13. IPCS framework for analyzing the relevance of a noncancer mode of action for humans.
Boobis AR; Doe JE; Heinrich-Hirsch B; Meek ME; Munn S; Ruchirawat M; Schlatter J; Seed J; Vickers C
Crit Rev Toxicol; 2008; 38(2):87-96. PubMed ID: 18259981
[TBL] [Abstract][Full Text] [Related]
14. PPARalpha agonist-induced rodent tumors: modes of action and human relevance.
Klaunig JE; Babich MA; Baetcke KP; Cook JC; Corton JC; David RM; DeLuca JG; Lai DY; McKee RH; Peters JM; Roberts RA; Fenner-Crisp PA
Crit Rev Toxicol; 2003; 33(6):655-780. PubMed ID: 14727734
[TBL] [Abstract][Full Text] [Related]
15. Thiazopyr and thyroid disruption: case study within the context of the 2006 IPCS Human Relevance Framework for analysis of a cancer mode of action.
Dellarco VL; McGregor D; Berry SC; Cohen SM; Boobis AR
Crit Rev Toxicol; 2006; 36(10):793-801. PubMed ID: 17118729
[TBL] [Abstract][Full Text] [Related]
16. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
17. Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens.
Bercu JP; Jolly RA; Flagella KM; Baker TK; Romero P; Stevens JL
Regul Toxicol Pharmacol; 2010 Dec; 58(3):369-81. PubMed ID: 20801182
[TBL] [Abstract][Full Text] [Related]
18. A strategy for establishing mode of action of chemical carcinogens as a guide for approaches to risk assessments.
Butterworth BE; Conolly RB; Morgan KT
Cancer Lett; 1995 Jun; 93(1):129-46. PubMed ID: 7600540
[TBL] [Abstract][Full Text] [Related]
19. Case study: weight of evidence evaluation of the human health relevance of thiamethoxam-related mouse liver tumors.
Pastoor T; Rose P; Lloyd S; Peffer R; Green T
Toxicol Sci; 2005 Jul; 86(1):56-60. PubMed ID: 15716475
[TBL] [Abstract][Full Text] [Related]
20. Are tumor incidence rates from chronic bioassays telling us what we need to know about carcinogens?
Gaylor DW
Regul Toxicol Pharmacol; 2005 Mar; 41(2):128-33. PubMed ID: 15698536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
